Last Updated: June 25, 2026

CLINICAL TRIALS PROFILE FOR NORGESIC


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NORGESIC

Trial ID Title Status Sponsor Phase Start Date Summary
NCT07109882 ↗ Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain RECRUITING University of Baghdad PHASE4 2025-07-22 To evaluate the clinical effectiveness of chlorzoxazone in comparison to orphenadrine Citrate in relieving the orofacial pain in bruxers. Subjects and Methods: 60 patients above 15-years old complaining of orofacial and temporomandibular disorder/pain, with no history of chronic systemic illness, will be recruited. Patients will randomly be allocated into two groups (n=30): the first group will receive Relaxon (chlorzoxazone) twice daily for two weeks, while the second group will receive Norgesic (orphenadrine Citrate) twice daily for two weeks as well. Pain severity will be assessed by Visual Analogue Scale (VAS) at day 0, 7, and day 14. In addition, a temporomandibular joint (TMJ) evaluation form will be utilized to assess the TMJ parameters before and after initiation of the treatment protocol, i.e at 0 and 14 days. Non parametric statistical analysis will be conducted to explain the results using SPSS V29.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NORGESIC

Condition Name

Condition Name for NORGESIC
Intervention Trials
Bruxism 1
Orofacial Pain 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NORGESIC
Intervention Trials
Facial Pain 1
Bruxism 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NORGESIC

Trials by Country

Trials by Country for NORGESIC
Location Trials
Iraq 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NORGESIC

Clinical Trial Phase

Clinical Trial Phase for NORGESIC
Clinical Trial Phase Trials
PHASE4 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NORGESIC
Clinical Trial Phase Trials
RECRUITING 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NORGESIC

Sponsor Name

Sponsor Name for NORGESIC
Sponsor Trials
University of Baghdad 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NORGESIC
Sponsor Trials
OTHER 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.